Literature DB >> 319939

Absorption of rifampin from various preparations and pharmaceutic forms.

P Männistö.   

Abstract

The absorption of 9 rifampin preparations was measured in two seaparate crossover studies on 10 healthy female volunteers. In the first set of experiments, one of the three capsule preparations was absorbed more slowly than the other ones. The absorption of two syrup preparations was nearly twice that of the best capsule preparation. In the second set, the absorption of the commercial tablets appeared to be somewhat faster than that of the reference capsule preparation. One tablet dissolved slowly in vitro and yielded very low serum concentrations. On the basis of these results the equiactive dose of rifampin in syrup form may be 25% to 50% lower than that of the other forms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319939     DOI: 10.1002/cpt1977213370

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

2.  Bactericidal effect of combinations of antimicrobial drugs and antineoplastic antibiotics against gram-negative bacilli.

Authors:  J Michel; J Y Jacobs; T Sacks
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

3.  Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin.

Authors:  A Mittal; P S Seshadri; H K Prasad; M Sathish; I Nath
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

5.  Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  P Brian Smith; C Michael Cotten; Mark L Hudak; Janice E Sullivan; Brenda B Poindexter; Michael Cohen-Wolkowiez; Felix Boakye-Agyeman; Andrew Lewandowski; Ravinder Anand; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.938

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.